Delveinsight Business Research LLP

DelveInsight’s ‘Generalized Myasthenia Gravis (gMG)—Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the Generalized Myasthenia Gravis (gMG), historical and forecasted epidemiology as well as the market trends in the United States, EU-4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Generalized Myasthenia Gravis (gMG) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Generalized Myasthenia Gravis (gMG) symptoms market size from 2019 to 2032 segmented by the seven major markets. The report also covers current Generalized Myasthenia Gravis (gMG) symptoms, diagnostic and treatment practice guidelines/algorithm,s and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Some of the key facts of the Generalized Myasthenia Gravis Market:

• Among EU5 countries, Germany had the highest number of prevalent cases of Generalized Myasthenia Gravis (gMG) (~14,700 cases) in 2021.

• Italy had the lowest prevalent population of Generalized Myasthenia Gravis (gMG) (8,800 cases) in 2021.

Got queries? Click here to know more about the Generalized Myasthenia Gravis Market Landscape

Generalized Myasthenia Gravis Overview

Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body’s own tissues. In MG, that attack interrupts the connection between nerve and muscle—the neuromuscular junction. MG is characterized mostly by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab). The diagnosis of MG is mostly clinical, and laboratory investigations and procedures usually aid the clinician in confirming the clinical findings. The diagnosis of MG is done through various tests such as serological tests, edrophonium tests, ice-pack tests, imaging, and other laboratory test.

ØMG remains one of the most challenging medical diagnoses due to its fluctuating character and the similarity of its symptoms to those of other disorders, as there are no international consensus guidelines.

Generalized Myasthenia Gravis Epidemiology Insights

• According to the Muscular Dystrophy Association, Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body’s own tissues. In MG, that attack interrupts the connection between nerve and muscle—the neuromuscular junction. MG is characterized by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab).  

• In 2021, the total prevalent cases of gMG were the highest in the US, with approximately 40,000 cases, and lowest in Italy with approximately 8,800 cases.

• There were approximately 13,500 males and 26,500 females affected by gMG in the United States in 2021 and it is estimated that the prevalence will increase and reach up to 15,500 and 30,300 in males and females by 2032.

 Generalized Myasthenia Gravis Epidemiology Segmentation

• Generalized Myasthenia Gravis diagnosed prevelant  cases 

• Generalized Myasthenia Gravis gender-specific cases  

• Generalized Myasthenia Gravis autoimmunobodies specific cases 

Generalized Myasthenia Gravis Market Outlook 

The Generalized Myasthenia Gravis (gMG) market outlook helps to better understand the historic, current and forecasted Generalized Myasthenia Gravis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Generalized Myasthenia Gravis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the Generalized Myasthenia Gravis market in the 7MM is expected to grow steadily during the study period 2019–2032.

Learn more by requesting for sample @ Generalized Myasthenia Gravis Market Trends

Generalized Myasthenia Gravis Key Companies

• UCB Biopharma

• Horizon Therapeutics

• And many others 

Generalized Myasthenia Gravis Therapies

• Rozanolixizumab

• Uplizna (Inbilizumab)

• And many more 

Table of Contents

1.   Key Insights 

2.   Report Introduction 

3.   Executive Summary of Generalized Myasthenia Gravis     

4.   Disease Background and Overview

5.   Epidemiology and patient population

6.   Generalized Myasthenia Gravis   Emerging Therapies

7.   Generalized Myasthenia Gravis   Market Outlook

8.   Market Access and Reimbursement of Therapies

9.   Market Drivers 

10.   Market Barriers 

11.   Appendix

12.   Generalized Myasthenia Gravis   Report Methodology

13.   DelveInsight Capabilities

14.   Disclaimer

Click here to read more about Generalized Myasthenia Gravis Market 

Related Reports 

Generalized Myasthenia Gravis Epidemiology Forecast to 2032

DelveInsight’s “Generalized Myasthenia Gravis   – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Generalized Myasthenia Gravis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com